IVDR-certified and clinically proven: Devyser RHD
RhD incompatibility remains a critical concern in prenatal care, with the potential to cause...
At present, FH is greatly underdiagnosed, and most cases are not discovered until the affected individual suffers his or her first cardiovascular event.
This paper by Peter Benedek and Kristina Duvefelt, Karolinska University Hospital, Stockholm, Sweden, introduces the clinical diagnosis, indicators and symptoms, and treatment of FH, before examining the background and current status of genetic testing for FH, and new best practices enabled by Next Generation Sequencing.
At present, FH is greatly underdiagnosed, and most cases are not discovered until the affected individual suffers his or her first cardiovascular event.
This paper by Peter Benedek and Kristina Duvefelt, Karolinska University Hospital, Stockholm, Sweden, introduces the clinical diagnosis, indicators and symptoms, and treatment of FH, before examining the background and current status of genetic testing for FH, and new best practices enabled by Next Generation Sequencing.
RhD incompatibility remains a critical concern in prenatal care, with the potential to cause...
Read More
Devyser today announced the global launch of Devyser Genomic Blood Typing, a next-generation...
Read More
Devyser, a pioneer in advanced genetic testing solutions, proudly announces the global launch of...
Read More
Devyser, a leading provider of advanced genetic testing solutions, has been awarded a significant...
Read More